Jeetinder Singh Mahal Sells 900 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock

Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Jeetinder Singh Mahal sold 900 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $22.11, for a total transaction of $19,899.00. Following the transaction, the chief operating officer now owns 25,009 shares in the company, valued at approximately $552,948.99. The trade was a 3.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jasper Therapeutics Stock Performance

Shares of JSPR opened at $20.60 on Friday. The stock has a 50 day simple moving average of $21.00 and a 200 day simple moving average of $20.86. Jasper Therapeutics, Inc. has a 52-week low of $4.24 and a 52-week high of $31.01. The firm has a market capitalization of $309 million, a PE ratio of -4.35 and a beta of 2.18.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on JSPR. Evercore ISI restated an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a report on Monday, August 26th. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research report on Thursday, October 24th. BMO Capital Markets initiated coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Finally, JMP Securities restated a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $73.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Samsara BioCapital LLC raised its holdings in shares of Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after acquiring an additional 59,642 shares during the period. Ally Bridge Group NY LLC raised its stake in shares of Jasper Therapeutics by 82.7% in the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after purchasing an additional 180,852 shares during the period. Braidwell LP acquired a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at about $9,091,000. Bank of New York Mellon Corp bought a new stake in shares of Jasper Therapeutics in the second quarter valued at about $740,000. Finally, Verition Fund Management LLC acquired a new position in shares of Jasper Therapeutics during the third quarter worth about $477,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.